Journal article

The in-vitro anticoagulant effect of rivaroxaban in neonates

Chantal Attard, Paul Monagle, Dagmar Kubitza, Vera Ignjatovic

Blood Coagulation and Fibrinolysis | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014


The use of anticoagulants in neonates is increasing because of the medical advances improving the long-term survival of very sick infants who are at risk of venous thromboembolism (VTE). Current anticoagulation therapy in neonates is less than ideal, because of the physiological differences compared to children and adults regarding the pathophysiology of thrombosis and pharmacology of the drug. Limitations associated with conventional anticoagulants have prompted the development of novel drugs that specifically target the key proteins in the coagulation system. Rivaroxaban is the first oral, direct Factor Xa inhibitor available for the prevention of VTE in adults. Its predictable pharmacokin..

View full abstract